Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing despite a decline in Prenatal Health. The company launched its Precise Molecular Residual Disease (MRD) assay and received FDA approval for the MyChoice CDx test as a companion diagnostic for ovarian cancer treatment. While reporting a GAAP net loss of $34.1 million, Myriad reaffirmed its full-year 2026 revenue guidance of $860-$880 million, expecting stronger second-half performance. The company is advancing new product launches, including an AI-enabled prostate cancer test, positioning for growth in 2027 and beyond.
Century Aluminum Company announced it will report its second quarter 2026 earnings on August 6, 2026, after the market closes. The company will also host a live conference call at 5:00 p.m. Eastern time the same day, accessible via its website. This ...
Blue Gold Limited was notified by Nasdaq that it does not meet the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15 million, based on market values from June 10 to July 23, 2026. The company has 180 days, until January 20, 2027...
Sun Communities reported a strong Core Funds from Operations (FFO) of $1.84 per share for Q2 2026, surpassing its guidance range of $1.71 to $1.79. However, the company posted a net loss of $8.08 per diluted share, mainly due to losses from discontin...
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
